Mikhail Blagosklonny Uses Oncotarget to Address Medical Issues

As a leading cause of morbidity as well as mortality in the world, cancer has been a threat to the medical fraternity. The new cases of death caused by cancer have risen to approximately 70% over the past decades. In order to deal with the cases of death caused by cancer, scientists, researchers as well as donors from different walks of life have converged their ideas with the aim of generating therapies that have a curative nature. The main objective of coming together is coming up with solutions. One such scientist who has been instrumental in the battle against cancer and age-related diseases is Mikhail Blagosklonny.

Experience

As an expert in cancer biology as well as treatment therapies, Mikhail has been developing different therapies with the aim of reaching out to the affected patients. Coupled with a strong academic background, Mikhail has explored different treatment options thanks to his extensive experience in research. Through his experiences, he has been able to develop successful therapies. Blagosklonny has proven to the medical field that modern treatment methods can be implemented to cure diseases. Most of his therapies have brought forth revolutionary treatment options.

Research

Blagosklonny is a research scientist and renowned oncologist who has made a name for himself in the medical field. He is prominent for having authored and co-authored many book chapters. He has also authored over 170 articles concerning cancer as well as age-related diseases. The topics of discussion include the generation of cancer cells and their progressive mutation in the host. This topic covers their cycle as well as apoptosis and autophagy. Blagosklonny’s works focus on the theory of aging called target of rapamycin.

TOR

Also abbreviated as TOR Signaling, Blagosklonny states that this theory plays an instrumental role in the treatment of cancer. It prolongs life by delaying autophagy as well as promoting cellular synthesis of proteins. This process is important because it slows down the aging process of human cells. This in turn curbs age-related diseases. In the same scenario, Blagosklonny proved that the over- expression of target of rapamycin would inhibit autophagy. This in turn leads to the growth of cancerous tumors. To Blagosklonny, it is vital to understand the entire process of autophagy. This is because with a clear understanding, it is easy to administer treatment.

Education and Career

Aside from being a research scientist, Mikhail Blagosklonny is a scholar. His experience extends beyond basic research. He presently serves as a professor at the Institute of Roswell Park, a cancer research institute. He has been serving in that institution since 2009. In 2002, Blagosklonny was appointed as a lead specialist in experimental as well as internal medicine. This saw his appointment as an associate professor at the New York College of Medical Studies. As an alumnus of the University of First Pavlov, he has a lot of achievement to show for his experience. Presently, he is the chief editor of Oncotarget. This is a peer-reviewed journal that addresses scientific issues related to various medical journals. Through Oncotarget, Blagosklonny has addressed various medical issues in regards to cancer and its treatment.

Leave a Reply